Compare Davita Inc (DVA) vs GXO Logistics Inc (GXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs GXO Logistics Inc — how do they compare? Davita Inc trades at $227.08 (market cap $14.92B), while GXO Logistics Inc trades at $51.92 (market cap $5.71B). The key difference: Davita Inc is far larger — about 2.6× GXO Logistics Inc's market cap, and Davita Inc is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals.
| DVA | GXO | |
|---|---|---|
Market Cap | $14.92B | $5.71B |
Sector | Health | Industrials |
52-Week High | $235.71 | $65.59 |
52-Week Low | $103.87 | $45.52 |
Enterprise Value | $27.47B | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
GXO Logistics trades at $48.99, down 3.2% today, with a bearish technical outlook despite strong analyst support. The company shows solid revenue growth with Q1 2026 earnings beating expectations at $0.50 per share versus $0.37 expected. Recent partnerships with major retailers and expansion in Europe highlight business momentum, though thin profit margins and competitive pressures from Amazon pose challenges.
Wall Street remains bullish with 16 buy ratings and a $69.33 price target suggesting 41% upside. However, technical indicators signal near-term weakness, and the stock faces execution risks in maintaining growth against industry competition. The upcoming Q2 earnings on August 5 will be critical for validating the positive fundamental trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
